The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model by Lai, Ming-Derg et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Genetic Vaccines and Therapy
Open Access Research
The effects of DNA formulation and administration route on cancer 
therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung 
cancer animal model
Ming-Derg Lai1,2,3, Meng-Chi Yen2, Chiu-Mei Lin4,5, Cheng-Fen Tu1, Chun-
Chin Wang6, Pei-Shan Lin6, Huei-Jiun Yang1 and Chi-Chen Lin*6,7
Address: 1Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Taiwan, 2Institute of Basic 
Medicine, College of Medicine, National Cheng Kung University, Taiwan, 3Center for Gene Regulation and Signal Transduction Research, National 
Cheng Kung University, Tainan, Taiwan, 4School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 5Department of 
Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan, R.O.C, 6Institute of Medical Technology, College of Life Science, 
National Chung Hsing University, Taiwan and 7Department of Medical Research and Education, Taichung-Veterans General Hospital, Taichung, 
Taiwan
Email: Ming-Derg Lai - a1211207@mail.ncku.edu.tw; Meng-Chi Yen - iqri@hotmail.com; Chiu-Mei Lin - james@bioware.com.tw; Cheng-
Fen Tu - dnavaccine@hotmail.com; Chun-Chin Wang - tony10600@yahoo.com.tw; Pei-Shan Lin - butterfly7557@hotmail.com; Huei-
Jiun Yang - snowangel0209@hotmail.com; Chi-Chen Lin* - lincc@dragon.nchu.edu.tw
* Corresponding author    
Abstract
Background: Tyrosine kinase inhibitor gefitinib is effective against lung cancer cells carrying
mutant epidermal growth factor receptor (EGFR); however, it is not effective against lung cancer
carrying normal EGFR. The breaking of immune tolerance against self epidermal growth factor
receptor with active immunization may be a useful approach for the treatment of EGFR-positive
lung tumors. Xenogeneic EGFR gene was demonstrated to induce antigen-specific immune
response against EGFR-expressing tumor with intramuscular administration.
Methods: In order to enhance the therapeutic effect of xenogeneic EGFR DNA vaccine, the
efficacy of altering routes of administration and formulation of plasmid DNA was evaluated on the
mouse lung tumor (LL2) naturally overexpressing endogenous EGFR in C57B6 mice. Three
different combination forms were studied, including (1) intramuscular administration of non-
coating DNA vaccine, (2) gene gun administration of DNA vaccine coated on gold particles, and (3)
gene gun administration of non-coating DNA vaccine. LL2-tumor bearing C57B6 mice were
immunized four times at weekly intervals with EGFR DNA vaccine.
Results: The results indicated that gene gun administration of non-coating xenogenic EGFR DNA
vaccine generated the strongest cytotoxicty T lymphocyte activity and best antitumor effects.
CD8(+) T cells were essential for anti-tumor immunityas indicated by depletion of lymphocytes in
vivo.
Conclusion: Thus, our data demonstrate that administration of non-coating xenogenic EGFR
DNA vaccine by gene gun may be the preferred method for treating EGFR-positive lung tumor in
the future.
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Background
The epidermal growth factor receptor (EGFR) is a transmem-
brane glycoprotein, which consists of three domains: an
extracellular ligand-binding domain that recognizes and
binds to specific ligands, a hydrophobic membrane-span-
ning region, and an intracellular catalytic domain that serves
as the site of tyrosine kinase activity [1,2]. High EGFR protein
expression was observed in several types of cancer including
breast, bladder, colon and lung carcinomas [3-6]. This
involvement in cancer progression and a negative prognosis
makes EGFR an attractive target for molecule therapy [7].
Various therapeutic strategies have been developed to block
EGFR signaling, with the most frequent strategies involving
monoclonal antibodies and small molecule tyrosine kinase
inhibitors that are designed to directly against receptor or
specifically inhibit EGFR enzymatic activity [8-10]. However,
some clinical studies indicated that tumors overexpressing
EGFR did not show a significant clinical response to anti-
body-based or small molecule inhibitor therapy in lung can-
cer, Searching for correlates, it has been found that the
presence of certain kinase domain mutations in EGFR gene
appear to predict responsiveness [11-13]. Hence, new strate-
gies are required to treat tumors overexpressing normal
EGFR.
Antigen-specific active immunotherapy is another poten-
tial therapeutic approach for the treatment of EGFR-posi-
tive tumor cells by breaking of immune tolerance against
wild type or mutant-type EGFR. Since the anti-EGFR anti-
body was not effective, the active immunotherapy may
need to induce both humoral and cellular immunity.
DNA vaccine apparently fulfills such a requirement [14].
Furthermore, DNA vaccine offer many advantages includ-
ing induction of a long-lived immune response, better sta-
bility, and easy preparation in large quantities than other
conventional vaccines such as peptide or attenuated live
or killed pathogens [15]. In addition, several studies have
indicated that tolerance to self antigens on cancer cells can
be overcome using active therapeutic immunization strat-
egies in preclinical animal model [16,17].
Intramuscular administration of xenogenic EGFR DNA
vaccine has been shown to break immune tolerance and
induce the specific antitumor immunity against EGFR-
positive tumors in a therapeutic preclinical model [18].
Two common routes of immunization have been for DNA
vaccination: needle intramuscular injection and epider-
mal gene gun bombardment. Many studies have shown
that gene gun-mediated immunization is more efficient
than needle intramuscular injection as it elicits similar
levels of humoral and cellular response [19,20]. However,
intramuscular injection of DNA induces a predominantly
Th1 response, whereas gene gun immunization with DNA
coated on gold evokes mainly Th2 response. The route of
immunization can influence the outcome of the immune
response through altering the interaction between the vac-
cine and different APCs at the site of injection [21]. Our
previous results suggested that gold particles used in gene
gun bombardment affected the induced-immune
response [22], because gene gun administration using
non-coating naked DNA vaccine elicited Th1-bias
immune response. Hence, the choice of the route of DNA
immunizations and formulation of DNA could thus rep-
resent an important element in the design of EGFR DNA
vaccine against EGFR-positive tumor.
In the present study, we aimed to determine how different
route of administration and formulation of plasmid DNA
could influence the efficacy of xenogenic EGFR DNA vac-
cine on a mouse lung tumor LL2 naturally overexpressing
endogenous EGFR. We analyzed and compared the
immunological and antitumor responses generated by the
plasmid DNA encoding extracellular domain of human
EGFR(a.a 1–621, Sec-N'-EGFR) administrated through
three different methods: needle intramuscular adminis-
tration using non-coating DNA (i.m), gene gun adminis-
tration using gold-coated DNA and gene gun
administration using non-coating DNA. Our results indi-
cated that the routes of administration and formulation of
DNA clearly affected the therapeutic response by altering
immune pathway. Gene gun administration using non-
coating plasmid DNA induced the best anti-tumor
immune response in LLC2 animal lung cancer animal
model, which may provide the basis for the design of
DNA vaccine in human clinical trial in the future.
Methods
Animals, Cell lines and antibodies
Inbred female C57BL/6 mice (6–8 weeks of age) weighing
18–20 g were used. Animal experiments were approved by
the National Cheng Kung University animal welfare com-
mittee. LL2 is a cell line derived from Lewis lung carcinoma
passaged routinely in C57BL/6 mice [23]. B-16 F10
melanoma cell line and colon carcinoma cell line CT-26
were obtained from American Type Culture Collection
(Manassas, VA, USA). Antibody against the extracellular
domain of mouse EGFR (N20; Santa cruz) was used for
Western blotting analysis of the expression of EGFR in these
cell lines. Antibody against mouse extracellular EGFR (N20;
Santa cruz) and FITC-conjugated donkey against goat IgG
secondary Ab (Jackson Immuno Research Laboratories, Inc)
were used for detection of surface EGFR in LL2 cells. Flow
cytometry analysis was performed with a FACSCalibur (BD
Bioscience, Mountain View, CA, USA).
Construction and Preparation of DNA vaccine
A431 cells were harvested and total RNA was isolated
using a total RNA extraction kit (Viogene-Biotek Corp.,
Hsichih, Taiwan) according to the manufacturer's instruc-
tions. The RNA was subjected to reverse transcriptaseGenetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
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polymerase chain reaction (RT-PCR) for amplification of
the extracellular domain of the human EGFR gene (Sec-
N'-EGFR) using the primers GCAATCAAGCTTATGCGAC-
CCTCCG GGACGG and GCAATCTCTAGACACA GGT-
GGCACACATGGCC The PCR product of the expected size
was isolated, digested with HindIII and XbaI, and cloned
into the multiple cloning site of pcDNA3.1B+myc-his
(Invitrogen, San Diego, CA, USA). The plasmid DNA was
transformed into Escherichia coli DH5 and purified from
large-scale cultures using a QIAGEN Endofree Mega Kit
(Qiagen, Chatsworth, CA, USA).
In vitro transfection and Western blotting
COS-7 cells were transiently transfected with DNA plas-
mids by Lipofactamine 2000 (Invitrogen, San Diego, CA,
USA), and cells were harvested 18 h post transfection. Total
cell lysates were prepared by using 2× SDS gel loading
buffer(Tris-HCl pH 8.45, 90 mM, Glycerol 24%, SDS 4%).
Equal amounts of cell lysates (30 μg of total protein) were
separated by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and transferred onto PVDF membranes
(minipore). The membrane was blocked for 1 h at room
temperature in PBS containing 5% nonfat dried milk and
0.1% Tween 20 under gentle shaking. The membrane was
then incubated overnight with EGFR-specific monoclonal
antibody and the ound antibody was detected with a
1:2,000 dilution of horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin G (Cell Signaling Technol-
ogy, Inc, Danvers, MA, USA). The immobilon Western
chemiluminescent HRP substrate (Millipore Corporation,
Billerica, U.S.A) was used for Western blotting. The inten-
sity of each band was read by using a B UVP Biospectrum
AC System (UVP, Upland, CA, U.S.A)
Therapeutic efficacy of DNA vaccine on tumor growth
Mice were injected subcutaneously in the flank with 1 ×
106 LL2 cells in 0.5 ml of PBS. At day 5, Sec-N'-EGFR DNA
vaccine was administered by three different methods four
times at weekly intervals when tumors were palpable.
Control mice were injected with water containing no plas-
mid DNA. Tumor growth was monitored using caliper
twice a week. Subcutaneous tumor volumes were calcu-
lated using the formula for a rational ellipse: (m1 × m2 ×
m2 × 0.5236), where m1 represents the longer axis and
m2 the shorter axis. Mice were sacrificed when the tumor
volume exceeded 2500 mm3 or the mouse was in poor
condition and death was expected shortly. Significance of
differences in mice survival was tested by Kaplan-Meier
analysis.
DNA vaccination by needle intramuscular injection
For intramuscular needle-mediated DNA vaccination, 100
μg/mouse of Sec-N'-EGFR DNA vaccines or
pcDNA3.1B+myc-his DNA plasmid were administered
intramuscularly by syringe needle injection.
DNA vaccination by gene gun gold-coated DNA or naked 
non-coating DNA
The protocol and delivery device for DNA vaccination by
gene gun have been described previously [22]. Briefly, for
gold-coated DNA vaccination, plasmid DNA was coated
on gold particles (Bio-Rad, Hercules, CA, USA) at the ratio
of 1–2 μg of DNA per mg of gold particles, and was dis-
solved in 20 μl of 100% ethanol. The gold-coated DNA
was delivered to the shaved abdominal region of C57BL/
6 mice using a helium-driven low pressure gene gun (Bio
Ware Technologies Co. Ltd, Taipei, Taiwan) with a dis-
charge pressure of 40 psi. For non-coating DNA vaccina-
tion, 1–2 μg of Sec-N'-EGFR DNA in 20 μl of autoclaved
double-distilled water was directly added to the loading
hole near the nozzle, and delivered to the shaved abdom-
inal of mice using the same low pressure gene gun with a
discharge pressure of 60 psi.
Determination of anti-EGFR antibody titer in serum
Recombinant extracellular domain protein of human
EGFR (0.25 μg/well) (R&D Systems Inc) in 100 μl coating
buffer (sodium carbonate, pH 9.6) was added to micro-
titer plates (Nunc, Roskilde, Denmark) and incubated
overnight at 4°C. Nonspecific binding was blocked with
1% BSA in PBS buffer for 2 h and washed with PBS con-
taining 0.05% Tween 20 for three times. Mouse mono-
clonal anti-human EGFR antibody (20E12; Santa cruz)
was used to generate the standard curve. The titer of anti-
EGFR antibody in experimental mouse sera were deter-
mined by serial dilution and added to wells. Plates were
incubated for 2 h at 37°C, washed, and then incubated
with HRP-conjugated anti-mouse IgG (Cell Signaling
Technology). TMB substrate was used for colour develop-
ment. Absorbance was measured at 450 nm with an ELISA
reader (Sunrise, Tecan, Austria).
Serum passive transfer
LL2 tumor bearing B6 mice were immunized with DNA
vaccine four times. Blood was collected 4, 7, 10 days after
the last immunization, and serum was collected and
pooled within each group of mice. A 300 μl of the polled
sera was transferred by intraperitoneal injection into
recipient mice which was s.c challenged with 1 × 106 LL2
tumor cells 5 day before. Blood collected from LL2 tumor
bearing B6 mice without DNA vaccination was used as
control.
Intracellular staining
Spleen or lymph node cells(2.5 × 106 cells/ml) were har-
vested a day after last immunization and cultured in 48
well tissue culture plates (BD Biosciences) in the presence
of 5 μg/ml of recombinant EGFR protein and incubated at
37°C in a 5% CO2 humidified atmosphere for 18 h.
Thereafter, 5 μg/ml brefeldin A (BFA; Sigma, St. Louis,
MO) was added, and the cultures were incubated for anGenetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
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additional 6 hr. Cells were harvested and stained with PE-
anti-CD4 (eBioscience) and PE-anti-CD8 (eBioscience)
and then fixed with 4% paraformaldehyde for 30 min at
4°C. The cells were permeabilized with PBS containing
0.1% saponin for 5 min, after which FITC-anti-IFN-γ (eBi-
oscience) antibody was added for detection of intracellu-
lar cytokine in the presence of saponin for 45 min at 4°C.
For analysis, 100000 cells were acquired on a Facscalibur.
The results were analyzed using CellQuest (BD Bio-
sciences).
In vivo CTL assay
Spleen and inguinal lymph node cells from naive C57BL/
6 mice were labeled with 5 or 0.5 μM CFSE. Cells labeled
with 5 μM CFSE were pulsed with 5 μg/ml recombinant
EGFR protein at 37°C for 1 hr as target cells while the cells
labeled with 0.5 μM CFSE were left unpulsed as control
cells. Equal number (1 × 107) of the two target popula-
tions were mixed together and injected into mice i.v., such
that each mouse was injected i.v with a total of 2 × 107
cells in 150 μl of PBS. Spleens and inguinal lymph nodes
in recipient mice were harvested 18 hrs later and single-
cell suspensions were prepared. The proportions of differ-
entially CFSE-labeled target cells were analyzed by flow
cytometry. To calculate specific lysis, the following for-
mula was used: ratio = (percentage CFSE low/percentage
CFSE high). Percentage of specific lysis = [1 - (ratio for
unimmunized mice/ratio for immunized mice) × 100]
Histological analysis of lymphocyte infiltration
Tumor tissues were removed from mice one week after the
last vaccination and embedded in OCT compound
(Sakura Finetek Inc., USA) and then frozen in liquid nitro-
gen. Cryosections (5-μm) were made and fixed with 3.7%
formaldehyde and acetone. Endogenous peroxidase was
removed with 3.7% hydrogen peroxide, washed with PBS
three times and incubated with primary antibody anti-
CD4 (GK1.5;BD Biosciences Pharmingen, San Jose, CA),
or anti-CD8 (53-6.7; Pharmingen), overnight at 4°C.
After further reaction with peroxidase-conjugated second-
ary antibody, aminoethyl carbazole substrate kit (Zymed
Laboratories, San Francisco, CA) was used for color devel-
oping. For quantification of immune infiltrating cells, the
cells were counted with a light microscope with a 10× eye-
piece and a 40× objective lens. Three samples from three
mice were taken and analyzed for statistical significance
test.
Depletion of CD8+ or CD4+ T cells
T cell-depletion experiments have been described previ-
ously[16]. Briefly, C57BL/6 mice were injected i.p with rat
anti-mouse CD8 (2.43; 500 g), rat anti-mouse CD4 (GK
1.5; 300 μg), or control antibody (purified rat IgG; 500
μg). The depletions started 2 day before DNA vaccination,
followed by multiple injections at 7-day intervals. To con-
firm the efficiency of T cell depletion, flow cytometry anal-
ysis revealed that the >95% of the appropriate subset was
depleted
Statistical Analysis
The animal experiments to evaluate immune responses
were repeated at least two times (n = 3 per group). SE val-
ues were calculated with GraphPad Prism 4 software
(GraphPad Software; San Diego, CA, USA), and P value
less than 0.05 was considered statistically significant.
Comparison of the survival rate was carried out by using
Kaplan-Meier method and log-rank test in GraphPad
Prism 4 software.
Results
The expression of EGFR in Mouse Cancer Cell Lines
The expression of EGFR in several cancer cell lines was
determined by Western blotting using antibodies that rec-
ognize the N-terminus of mouse EGFR (Fig. 1A). The
expression of EGFR in LL2 lung tumor cells was the high-
est among three cell lines examined. In addition, we fur-
ther confirmed surface expression of EGFR with flow
cytometry (Fig. 1B). Therefore, the LL2 lung tumor in B6
mice is a good animal model to study the efficacy of the
EGFR DNA vaccine.
Construction and Characterization of Sec-N'-EGFR DNA 
vaccine
We first constructed the plasmid encoding the N-terminal
extracellular domain of human EGFR (a.a. 1–621) and
named the plasmid "Sec-N'-EGFR" (Fig. 2). The COS-7
cells were transfected with Sec-N'-EGFR DNA and the
expression of extracellular domain of human EGFR was
determined with western blotting. The Sec-N'-EGFR DNA
plasmids expressed the extracellular domain of human
EGFR in vitro (Fig. 2).
Efficacy of Sec-N'-EGFR DNA Vaccine in Mice with 
Established Tumors
At day 0, we injected mice subcutaneously with 1 × 106
LL2 tumor cells. At day 5, when the tumor was palpable,
we immunized the mice with Sec-N'-EGFR DNA vaccine
four times at weekly intervals via three different methods:
intramuscular injection (i.m), gene gun administration of
gold-coated DNA, and gene gun administration of non-
coating DNA. Non-coating Sec-N'-EGFR DNA vaccine
administered by gene gun statistically delayed the growth
of LL2 tumors when compared with control mice (Fig.
3A). In addition, the survival portion of vaccinated mice
indicated that the therapeutic efficacy appeared to be in
the order: g.g non-coating DNA vaccine mice group > g.g-
DNA coated gold particels or i.m DNA vaccine mice
groups >> control mice group (Fig 3B). The survival rate
of mice showed significant differences between the con-
trol mice and all three vaccinated mice groups (p < 0.01).Genetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
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Furthermore, the difference between g.g non-coating DNA
and the other two mice groups (i.m or g.g-DNA coated
gold particles) is also statistically significant (P < 0.05)(Fig
3B)
Humoral Immunity
To investigate the immunological mechanism underlying
the therapeutic effect of Sec-N'-EGFR DNA vaccine, the
induction of anti-EGFR antibodies was examined in mice
serum. Specific antibodies against EGFR proteins in mice
serum samples were tested by ELISA using recombinant
extracellular domain human EGFR proteins. The results
showed that anti-EGFR antibodies were detected in all
mice vaccinated with Sec-N'-EGFR DNA vaccine; however,
the serum from g.g DNA coated gold particles and i.m
mice groups contained higher levels of anti-EGFR anti-
bodies than g.g-non-coating DNA mice group (Fig 4A). To
further confirm the role of antibody in this therapeutic
Sec-N'-EGFR DNA vaccine approach, the immune sera
from mice vaccinated with DNA vaccine was passively
transferred into mice with established LL2 tumors. The
result showed that mice receiving serum from i.m mice
group (p = 0.08) and g.g-DNA coated gold particles mice
group(p < 0.05) showed prolong mice survival compared
with mice injected with serum from control animals (Fig.
4B). The anti-EGFR antibody induced by Sec-N'-EGFR
DNA played a role in delay tumor progression although
the amount of antibody may not be correlated with anti-
tumor effects of three forms of therapeutic EGFR DNA
vaccine.
Cellular Immunity
To examine the specific immunologic cellular response to
Sec-N'-EGFR DNA vaccine using different administration
methods, spleen and lymph nodes were isolated from vac-
cinated mice. The lymphocytes were stained for the sur-
face CD4 and CD8 marker and intracellular IFN-γ after
recombinant human EGFR antigen stimulation. Non-
coating Sec-N'-EGFR administration by gene gun gener-
ated most functional EGFR-specific CD8+ T cell cells as
evidenced by their production of intracellular IFN-γ in the
lymph node(Fig 5A, B). In contrast, splenic lymphocytes
isolated from intramuscular injection of Sec-N'-EGFR
mice group had higher functional EGFR-specific CD4+
and CD8+ T cells when compared with i.m and g.g DNA
coated gold particles vaccinated mice groups, respec-
tively(Fig 5A, B). In addition, we also measured cytotoxic
T lymphocytes(CTLs) activity in mice immunized with
Sec-N'-EGFR DNA vaccine by three different methods. The
cytotoxic T lymphocytes(CTLs) effector function in spleen
appeared to be in the order i.m mice group > g.g-DNA
coated gold particles and g.g-non coating DNA mice
groups>> control group (illustrated in an individual
mouse in Fig. 6A and as group means in Fig. 6B). In con-
trast, the percent of specific cytotoxic T lymphocytes lysis
in inguinal lymph node of vaccinated mice indicated that
only non-coating Sec-N'-EGFR DNA administrated via
gene gun is sufficient to induce CTL effector function (Fig
6A, B). Hence, taken together, the number of functional
CD4+, CD8+ T cell and level of CTL activity in spleen and
inguinal lymph node were differentially affected by the
routes of administration and formulation of DNA vac-
cine.
To further demonstrate the importance of cellular immu-
nity in cancer therapy, we examined the histology of the
tumors. We observed CD4+ lymphocyte tumor infiltra-
tions were detected in all mice groups (Fig. 7A and Table
1). However, tumors form g.g DNA coated gold particles
mice group showed a greater infiltration of CD4+ lym-
phocytes compared with other treatment groups and con-
Overexpression of EGFR in LL2 lung cancer cell line Figure 1
Overexpression of EGFR in LL2 lung cancer cell line. 
The expression of EGFR in various cell lines was analyzed by 
Western blotting with monoclonal antibody against EGFR. 
(B) Flow cytometry analysis of membrane EGFR in LL2 cells. 
LL2 cells were stained with monoclonal antibody against the 
extracellular domain of mouse EGFR, followed by FITC-con-
jugated mouse anti-goat secondary antibody (gray histo-
gram). Normal mouse IgG mAb was used as the negative 
control (white histogram).Genetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
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trol group. As for tumor infiltration of CD8+ T cell, we
observed considerably increase of CD8+ lymphocyte in
the g.g-non coating DNA mice group (Fig. 7B and Table 1)
and minor increase of CD8+ lymphocytes in the i.m and
g.g-gold mice group in comparison with control mice
group. Hence, the results suggested a correlation between
the therapeutic efficacy of gene gun administration of
non-coating EGFR DNA vaccine and the amount of CD8+
T cell tumor infiltration.
The effects of CD8+ T Cell- Depletion or CD4+ T Cell- De 
pletion on the Efficacy of Gene Gun Administration of 
Non-coating EGFR DNA vaccine
The efficacy of gene gun administration of non-coating
EGFR DNA vaccine was the best among three types of
EFEGFR DNA vaccines, and seemed to correlate with
CD8+ T cells. Therefore, CD8+ T cells were depleted with
monoclonal antibody 2.43 to determine whether CD8+
lymphocytes were required for the therapeutic efficacy.
We performed CD8+ T cell-depletion at weekly intervals
during the entire experiment, and the protocol is shown
in Fig. 8A. Depletion of CD8+ lymphocytes completely
Characterization of Sec-N'-EGFR DNA vaccines Figure 2
Characterization of Sec-N'-EGFR DNA vaccines. (A) Schematic diagram of the Sec-N'-EGFR expressing vectors. The N-
terminal extracellular portion of the human EGFR gene was constructed to pcDNA3.1B+myc-his plasmid. Transcription is 
directed by cytomegalovirus (CMV) early promoter/enhancer sequences. The plasmid was named Sec-N'-EGFR (B) Expression 
of Sec-N'-EGFR was evaluated with transient transfection into COS-7 cells in vitro., and western blot analysis of sec-N-termi-
nal EGFR protein. Whole cell lysates were collected from Cells transfected with Sec-N'-EGFR (lane 2), or control 
pcDNA3.1B+myc-his plasmid (lane 1), and analyzed with western blotting.Genetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
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Therapeutic effects of Sec-N'-EGFR DNA vaccine administered by three different methods on established tumor in B6 mice Figure 3
Therapeutic effects of Sec-N'-EGFR DNA vaccine administered by three different methods on established 
tumor in B6 mice. Five days after subcutaneous tumor implantation with 1 × 106 LL2 tumor cells., mice were administrated 
with DNA vaccine four times (day 5, 12, 19, 26) at weekly intervals; (A) tumor volume was measured at the indicated time. 
Data are means of the animals per group; bars, ± S.D. (B) lifespan of mice after subcutaneous challenge. The survival data were 
subjected to Kaplan-Meier analysis. The digit in the parenthesis is the number of mice in the experiment. The symbol (*) indi-
cates a statistically significant difference when compared with the control saline mice (P < 0.01). The symbol (**) indicates a 
statistically significant difference when compared with the i.m and g.g gold-coated DNA group mice (P < 0.05) or control mice 
(P < 0.001). The experiments were repeated 2 times with similar results.Genetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
Page 8 of 13
(page number not for citation purposes)
abolished the therapeutic efficacy of Sec-N'-EGFR DNA
vaccine delivered via g.g non-coating DNA method (Fig.
8B). On the other hand, it is known that CD4+ T cells have
important regulatory functions for CD8+ CTL and anti-
body responses [24]. Hence, we also depleted CD4 +T
cells with monoclonal antibodies GK1.5 and at weekly
intervals during the entire experiment. The results showed
that depletion of CD4+ T cell in mice did not affect the
The presence and the therapeutic efficacy of anti-EGFR antibody in serum from the DNA vaccine group of mice Figure 4
The presence and the therapeutic efficacy of anti-EGFR antibody in serum from the DNA vaccine group of 
mice. A) Anti-EGFR antibody titer in the mice serum. The serum anti-EGFR antibody in mice was determined with ELISA on 
dishes coated with the recombinant extracellular domain of human EGFR protein. The data represent the average titer of the 
sera from three mice in each group. The symbol (**) indicates a statistically significant difference when compared with the g.g 
non-coating DNA group mice (P < 0.05) or control mice (P < 0.001). B) B6 mice were treated with serum from control or vac-
cinated mice on day 5, 12, 19, 26 after s.c challenge with LL2 cells. The survival data were subjected to Kaplan-Meier analysis 
The symbol (*) indicates a statistically significant difference when compared with control mice group(P < 0.05). The experi-
ments were repeated 2 times with similar results.Genetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
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Flow cytometry analysis EGFR-specific CD4+ and CD8+ T cells that functionally secrete IFN-γ in vaccinated mice Figure 5
Flow cytometry analysis EGFR-specific CD4+ and CD8+ T cells that functionally secrete IFN-γ in vaccinated 
mice. A) the number of IFN-γ-producing EGFR-specific CD4+ and CD8+ T cells in both spleens and inguinal lymph node was 
determined using flow cytometry in the presence of recombinant extracellular domain of human EGFR. B). Data are expressed 
as the mean numbers of CD4+ (black sqaure) and CD8+ (black sqaure)IFN-γ+ cells/3 × 105 spleen cells or inguinal lymph node 
cells; bars, SE. The symbol(**)indicates a statistically significant difference when compared with other treatment groups(P < 
0.05). The data presented in this figure are from one representative experiment of two performed.Genetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
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In vivo CTL activity in vaccinated mice Figure 6
In vivo CTL activity in vaccinated mice. (A) In vivo EGFR-specific effector CTL are located throughout the secondary 
lymphoid system. A week after last DNA vaccination, an in vivo CTL using recombinant human EGFR protein pulsed spleno-
cytes or inguinal lymph node as targets was performed to assess in vivo CTL activity. (B) The percentages of specific lysis were 
calculated to obtain a numerical value of cytotoxicity with data from each experimental group of three mice averaged. The 
symbol(##) and the symbol(**)indicates a statistically significant difference when compared with other treatment groups(P < 
0.05). Similar results were obtained from two more repeated experiments (n = 3 per group).Genetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
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overall survival of mice administrated with non-coating
DNA vaccine via g, g (Fig. 8B). Thus, these results sug-
gested that CD8+ T cell played a major role in mediating
therapeutic efficacy of gene gun administration of non-
coating EGFR DNA vaccine
Discussion
In this study, we assessed the immunologic responses and
therapeutic antitumor effects of EGFR DNA vaccine deliv-
ered by three different methods: needle intramuscular
administration using non-coating DNA (i.m), gene gun
administration using DNA coated on gold particles (g.g-
coated gold particles) and gene gun administration using
non-coating DNA (g.g-non coating DNA) in an EGFR-
overexpressing LL2 lung tumor animal model. Our results
showed that non-coating Sec-N'-EGFR DNA vaccine
administrated via gene gun represents the most potent
regime for DNA administration. In addition, gene gun
administration using non-coating Sec-N'-EGFR DNA vac-
Table 1: Infiltrated lymphocytes at tumor sites within 
cryosectioned samples
Vaccine group CD4+ T cells CD8+ T cells
Control 6 ± 1 0
i.m 17 ± 2** 11 ± 5#
g.g -DNA coated gold particles 118 ± 24*** 4 ± 3#
g.g-non coating DNA 7 ± 2 23 ± 4##
Note: Cell count was performed at 400× magnification. Three 
samples and five randomly chosen fields/sample were evaluated. 
Results are expressed as mean ± standard deviation of 
immunohistochemical positive cells in the cryosection. GG: gene gun. 
The symbol (**) indicates a statistically significant difference when 
compared with the g.g non-coating DNA and control group (P < 
0.05). The symbol (***) indicates a statistically significant difference 
when compared with the i.m and g.g non-coating DNA group (P < 
0.05). The symbol (#) indicates a statistically significant difference 
when compared with the control group (P < 0.01). The symbol (##) 
indicates a statistically significant difference when compared with the 
i.m and g.g DNA coated gold particles group(P < 0.05).
Tumor infiltration of CD4+ and CD8+ T cells Figure 7
Tumor infiltration of CD4+ and CD8+ T cells. Tumors 
were excised from mice administrated with Sec-N'-EGFR, or 
control DNA vector by different delivery methods. Analysis 
of (A) CD4+ and (B) CD8+ T cells in cryosections of tumors 
was performed with staining with primary antibody specific 
for CD4+ and CD8+ cells respectively. Peroxidase-conju-
gated antibody was used as secondary antibody. Dark spots, 
peroxidase-stained cells. Similar results were obtained from 
two more repeated experiments (n = 3 per group).
The effects of CD8+ T cell-depletion or CD4+ T cell-deple- tion on the therapeutic effects of non-coating EGFR DNA  vaccine by gene gun administration (A) Protocol for deple- tion of CD8+ or CD4+ T cells in vivo Figure 8
The effects of CD8+ T cell-depletion or CD4+ T cell-
depletion on the therapeutic effects of non-coating 
EGFR DNA vaccine by gene gun administration (A) 
Protocol for depletion of CD8+ or CD4+ T cells in 
vivo. Tumor-bearing mice were injected i.p with 500 μg of 
anti-CD8 antibody or 300 μg of anti-CD4 antibody at weekly 
intervals starting from 2 days before the first inoculation of 
DNA vaccine. (B) Life span of B6 mice after sc challenge with 
LL2 tumor cells. ** represents statistically significant differ-
ence when compared to the control saline group of mice (P 
< 0.01). The experiments were repeated twice with experi-
mental groups.Genetic Vaccines and Therapy 2009, 7:2 http://www.gvt-journal.com/content/7/1/2
Page 12 of 13
(page number not for citation purposes)
cine generated higher EGFR-specific functional CD8+ T
cell and EGFR-specific CTL activity in vivo comparing to
other treatment groups. T cell-depletion experiment indi-
cated that CD8+ T cell played a major role in mediating
therapeutic efficacy of gene gun administration of non-
coating EGFR DNA vaccine
In this study, we observed that gold-coated Sec-N'-EGFR
DNA vaccine by gene gun generated higher antibody in
the serum than g.g-non-coating DNA mice group. In addi-
tion, mice receiving serum from g.g-DNA coated gold par-
ticles mice group(p < 0.05) showed prolong mice survival
when compared with mice injected with serum from con-
trol animals. These results suggested that anti-EGFR anti-
body produced also might be effective against EGFR-
overexpressing tumor in LL2 model. However, clinical
reports indicated that EGFR overexpression as detected by
immunohistochemistry has not been correlated with
response to small molecule EGFR inhibitor or anti-EGFR
antibody therapy. The presence of certain EGFR kinase
domain mutation appears to predict responsiveness better
[11-13]. It is possible that the mutations present in EGFR
precipitate the altered oncogenic signal and make EGFR
indispensable for tumor growth, which make the inhibi-
tor or antibody function to inhibit tumor growth. On the
other hand, the reaction of CTLs does not depend whether
the target molecules are indispensable or essential for the
growth of tumor cells. Therefore, CTL effector cell may be
useful against lung tumor with expressing wild type EGFR
or mutant type EGFR protein. Hence, our results suggest
that increase of Th1-like CTL immune response by admin-
istration of non-coating EGFR DNA vaccine may be the
most potential application of EGFR DNA vaccine in the
further clinical trials.
It was interesting to observe that administration route and
forms of DNA affected the CTL activity in the spleen and
inguinal lymph node differentially. Administration of
Sec-N'-EGFR DNA vaccine by needle intramuscular injec-
tion can induce stronger CTL activity in spleen than gene
gun administration of Sec-N'-EGFR DNA. In contrast,
administration of non-coating Sec-N'-EGFR DNA vaccine
via gene gun induced stronger CTL activity in inguinal
lymph node than other treatments The different outcome
of CTL activity may at least be explained by two reasons.
First, i.m and g.g administrations of DNA may induce
immune responses in different lymphoid compartments.
Skin administration of DNA by gene gun appears to initi-
ate responses by virtue of transfected epidermal Langer-
hans cells or antigen loaded epidermal Langerhans cells
moving into draining inguinal lymph nodes [25-27]. By
contrast, intramuscular injection of DNA initiated mainly
by cells that has moved in the blood to the spleen [25,28].
Second, Th1 immunity is critical for the induction of spe-
cific cell-mediated cytotoxic cells including tumor-specific
cytotoxic T lymphocytes in tumor-bearing mice. Our pre-
vious study demonstrated that administration of non-
coating DNA via gene gun induced a predominantly T
helper type 1 (Th1) response, whereas administration of
gold-coated DNA by gene gun elicited predominantly T
helper type 2 (Th2) responses [22]. Combination of these
two factors may determine the final CTL activity in spleen
and lymph nodes.
Conclusion
In summary, the therapeutic efficacy of Sec-N'-EGFR DNA
vaccine was dependent on the route of administration and
formulation of plasmid DNA (gold-coating or non-coat-
ing). More importantly, we have shown that non-coating
Sec-N'-EGFR DNA administration via gene gun represents
the most potent regimen for EGFR DNA vaccine against
EGFR-positive LL2 lung tumor and may be the preferred
choice in the future clinical trial.
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